Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from pivotal amblyopia trial
➤ Phase 2 clinical program for third-generation keratoconus treatment
➤ Study compares tolerability of standard drop vs. novel drug delivery device
➤ Phase 3 clinical studies for investigational presbyopia drop complete
➤ Orphan drug designation granted for fungal keratitis treatment
➤ Full rights regained for investigational dry AMD therapy
➤ ASCRS news and events
➤ Launch of IOL made with new ‘glistening-free’ material
➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group
➤ Acquisition of electrophysiology medical device company
➤ Licensing of investigational neuroprotective drug
➤ ASCRS news and events
➤ FDA approves first drug-eluting contact lens
➤ FDA accepts 510(k) submission for new femto-phaco device
➤ Phase 2 study begins to evaluate an immunomodulatory agent for dry eye
➤ Licensing agreement for optic nerve-protective therapy
➤ Phase 3 study to evaluate protein replacement solution for dry eye
➤ Study: Impact of age on SMILE outcomes
➤ ASCRS news and events
➤ FDA accepts NDA for anesthesia, pain management drug
➤ Five-year results with intracanalicular microstent
➤ Request for information about ocular imaging
➤ Post-hoc analysis of NMOSD treatment
➤ Investigational visual prosthesis implanted in blind patient
➤ ASCRS news and events
➤ Nerve growth factor being studied as a possible treatment for Sjogren’s-related dry eye
➤ Investigational RNA therapy doesn’t meet primary endpoint
➤ Phase 1 clinical trial for bioerodible, sustained anti-VEGF delivery
➤ Positive interim data for diabetic retinopathy treatment
➤ Positive results in trial for high-dose aflibercept
➤ Additional Phase 3 trial data for Beovu in DME
➤ ASCRS news and events
➤ FDA approves generic Restasis
➤ Phase 3 trial for novel, preservative-free drug delivery platform
➤ Enrollment complete for Phase 3 blepharitis trial
➤ Enrollment complete for Phase 3 mydriasis reversal study
➤ Path forward for resubmission of drug-device combination product
➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report
➤ ASCRS news and events
➤ FDA approves first bispecific antibody for the eye
➤ FDA approves treatment for rare uveal melanoma
➤ New data on clinical programs investigating phentolamine ophthalmic solution
➤ Phase 2 clinical trial results published for investigational drug targeting allergic conjunctivitis
➤ Patient dosing begins for gene therapy to treat X-linked retinitis pigmentosa
➤ New effort to research glaucoma
➤ ASCRS news and events
➤ FDA grants IND for Stargardt gene therapy
➤ Phase 2 clinical trial evaluates oral nicotinamide and pyruvate effect on visual function
➤ First ophthalmic formulation of bevacizumab moves toward FDA BLA submission
➤ Positive results for faricimab as an investigational treatment for wet AMD, DME
➤ Eye scans and AI predict risk of heart attack
➤ ASCRS news and events
➤ Study evaluates the potential for AI in cataract surgery
➤ Pre-clinical model for dry AMD
➤ Research finds up to 30% of wet AMD patients could stop injections
➤ Prospective study of a new home-based OCT device begins
➤ ASCRS news and events
➤ FDA clearance for viscodelivery system
➤ FDA approves IND application for immunomodulatory agent for dry eye
➤ Phase 2b results for sustained-release, IOP-lowering implant
➤ Positive topline Phase 2 results for investigational dry eye drug
➤ Phase 2 trials begin for two transdermal drug formulations
➤ Second pivotal trial begins for wet AMD gene therapy
➤ Alcon completes acquisition of Ivantis
➤ ASCRS news and events
